You are here: Industry Insights > COVID-19

News List

Parkway Clinical Laboratories Launches COVID-19 Immune Response Consumer Direct Access Testing prnewswire
June 16, 2020
Parkway Clinical Laboratories Inc. (PCL), announced it has launched COVID-19 Immune Response Serum Immunoglobin IGG Antibody test available directly to consumers.
MBio Delivers Rapid Cytokine Test System for COVID-19 Research prnewswire
June 16, 2020
Rapid Point-of-Care Test for Interleukin-6 (IL-6) to be used in Clinical Studies.
Red Cross announces testing of all blood donations for COVID-19 antibodies prnewswire
June 16, 2020
Resumed surgical procedures and patient treatments have resulted in an urgent need for blood donations.
Zydus Cadila inks licensing pact with Gilead for remdesivir expresspharma
June 16, 2020
The licence is royalty-free until another pharma product or vaccine is approved for the treatment or prevention of COVID-19 by the USFDA or EMA or the WHO announcing the end of the public health emergency.
Centre clarifies reasons for delay in approvals for remdesivir expresspharma
June 16, 2020
Informs that it is awaiting data on some crucial parameters from companies that have applied for manufacturing and marketing approvals.
Popular blood pressure medicines do not put patients at greater COVID-19 risk, new study finds expresspharma
June 16, 2020
Two blood pressure-lowering drug classes, called ACE inhibitors and ARBs, came under scrutiny after the US Centers for Disease Control and Prevention reported in April that 72 per cent of hospitalized COVID-19 patients 65 or older had hypertension.
10 Predictions on How COVID-19 Will Impact Middle Market M&A prnewswire
June 15, 2020
The coronavirus outbreak has impacted just about every aspect of daily life on a global scale, and middle market M&A is no exception.
FSD Receives FDA Approval to Design Trial for COVID-19 Treatment americanpharmaceuticalreview
June 15, 2020
FSD Pharma announced the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.
Eleva Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 15, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.
Study suggests current drug shortages in US will be worsened by COVID-19 pandemic europeanpharmaceuticalreview
June 15, 2020
A newly released paper has revealed that the shortages of medications in the US at present will be increased further due to the COVID-19 outbreak.